EGFR and neoplasm: Additional preclinical models, including ex-vivo tumour cultures and patient-derived xenografts, evaluating the reduction of drug sensitivity following CDK4/6 inhibitor treatment as well as synergistic potential of CDK4/6 and EGFR inhibitors in CDK4/6 inhibitor-naïve models are required to further confirm our observations.